Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)

Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)

Active, not recruiting · NCT03703050 · Registry updated 2026-04-02

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)	Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence	Active, not recruiting	Phase 2	2026-04-02		NCT03703050

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Gustave Roussy, Cancer Campus, Grand Paris	93

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Centre Léon Berard Lyon	Lyon	France	1
Centre Oscar Lambret	Lille	France	61
CHU Bordeaux	Bordeaux	France	67
CHU Bordeaux Hopital Pellegrin	Bordeaux	France	1
Chu de Nancy	Vandœuvre-lès-Nancy	France	2
CHU Mondor	Créteil	France	3
CHU Toulouse Hopital des Enfants	Toulouse	France	2
Gustave Roussy	Villejuif	France	17
Hôpital Saint Louis	Paris	France	22
Hôpital Trousseau	Paris	France	1
IUC Toulouse	Toulouse	France	1
Rigshospitalet	Copenhagen	Denmark	84
Women'S and Children'S Nhs Foundation Trust	Birmingham	United Kingdom	1